Click to slide down
Home » Grow » Sector Growth » Ambitious Essex Tech 50 » Ambitious Essex Tech 50 – 2026 » Arecor
Arecor Therapeutics plc is a clinical stage biopharmaceutical company focused on enhanced drug development and delivery for chronic conditions, such as diabetes and other cardiometabolic diseases. The company has a proprietary technology called Arestat® which improves product formats with enhanced properties ranging from greater safety and convenience through to superior therapeutic profiles. Arecor’s lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid acting insulin which is being co-developed for phase 2 clinical trials later in 2026, with US device company, Sequel Med Tech. Arecor is also developing a novel oral delivery platform for peptides. The company is listed on AIM (AIM: AREC).
• November 2025 – Arecor Enhanced IP Coverage for AT278 and Oral Delivery Technology. o AT278 IP – Arecor has strengthened its patent protection for its lead programme, AT278, the only ultra-concentrated and ultra-rapid acting insulin in development with the potential to enable longer-wear for existing automated insulin delivery (AID) systems and their future miniaturisation. A US patent has been granted to protect key formulations and uses of AT278. In addition, another patent with respect to AT278 intellectual property has been approved for grant by the European Patent Office, providing further patent protection in Europe. o Oral peptide delivery IP – Arecor has also filed a patent application with the European Patent office, claiming novel compositions to improve the oral bioavailability of complex peptides. Novel peptide therapeutics are proving to be highly effective to treat chronic conditions such as obesity, diabetes and other cardiometabolic diseases, and there is growing evidence that oral delivery improves patient compliance and adherence. Poor oral bioavailability remains a major barrier to developing convenient oral peptide therapies. Arecor is addressing this challenge through novel therapeutic formulations designed to improve the oral bioavailability of peptides. The new patent application protects the key formulation design space discovered in initial investigations with additional patent applications expected to follow as R&D progresses.
• September 2025 – Arecor signed a co-development agreement with Sequel Med Tech LLC, a company developing state-of-the-art insulin delivery technologies, to combine AT278 (500U/mL) with Sequel’s twiist™ Automated Insulin Delivery (AID) system powered by Tidepool. The Company also signed a royalty financing agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) which raised non-dilutive capital of up to $11 million (£8.2 million). Co-Development Agreement & Monetisation Deal
• September 2025 – Arecor received positive FDA feedback on Phase 2 clinical study design for ultra-concentrated and ultra-rapid acting insulin, AT278, in combination with an Automated Insulin Delivery (AID) system. Positive FDA Feedback on Phase 2 Study Design
• May 2025 – Arecor established a partnership with Skye Bioscience [Nasdaq: SKYE], a clinical-stage biotechnology company focused on obesity and other metabolic health disorders. The partnership aims to develop a novel, higher concentration formulation of Skye’s CB1 inhibitor, nimacimab, using Arecor’s proprietary formulation technology platform, Arestat™. Skye is evaluating nimacimab, a first-in-class CB1-inhibiting monoclonal antibody, in its Phase 2a CBeyond™ clinical trial in patients with obesity and overweight. Data from the initial 26-week treatment period is anticipated in late Q3 or early Q4 2025. Arecor Partnership with Skye Bioscience
• March 2025 – Arecor signed a formulation study agreement with a major global pharmaceutical partner. Under the terms of the agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to develop a novel formulation of the partner’s proprietary product with enhanced properties. The partner company will fully fund the formulation work with the potential for future license opportunities to follow. Collaboration with global pharmaceutical partner
• AT278 ultra-concentrated and ultra-rapid acting insulin – working with co-development partner, Sequel Med Tech, to prepare this lead programme for entry into Phase 2 clinical trial • Oral peptide delivery technology platform – development work, generating data to determine its feasibility and applicability
Essex is a great location for life science R&D companies with good transport links between London and Cambridge. It offers cutting-edge labs, strong academic and public sector partnerships, targeted funding, and inclusion in a dynamic innovation corridor -making it an ideal and strategic place to launch or scale operations for a company in the life sciences sector.
The Arestat® reformulation technology platform consists of a patented series of over ten different mechanistically defined families of specific combinations of excipients which, when selected and combined with a therapeutic medicine, will deliver novel formulations with enhanced properties that would otherwise be unachievable. Arestat® results in improved product formats with enhanced properties ranging from greater safety and convenience through to superior therapeutic profiles which can improve patient care and health outcomes. It can be applied to a broad range of products, notably antibodies, complex biologics, peptides and vaccines. Development of the formulations with enhanced properties using the Arestat® technology follows four key steps:
Collaboration is the life blood of the Biotech sector; the exchanging of ideas and working with people from different disciplines within life sciences can often make the difference between success and failure. This is because the biological processes behind a disease are often very complex and in turn, finding the answer for treatment. Within a drug development team, you will find specialists in biology, chemistry, bioinformatics, medics, regulatory experts, and increasingly, experts in AI. It’s not only the collaboration within a biotech organisation that is required. Biotechs will look externally for partners to help with the manufacture, testing and pharma licensors to take a programme through later stage clinical trials and eventual commercialisation. Collaboration is essential.
At Arecor we are seeking to build a high-performing, purpose driven organisation where people can thrive. We are all experts in our field, whether that is in the scientific or operational roles, and collaboration is anchored in our values and culture. The most in demand skills are strong formulation and analytical expertise, particularly in protein, peptide, and small-molecule development, alongside proficiency in techniques such as HPLC, mass spectrometry, and stability studies. However, it is the shared sense of purpose of creating treatments that improve patients’ lives by reducing the burden of their conditions that underlies everything.
Visit Arecor
